Successful Use of Recombinant Factor VIIa for Hemostasis During Total Knee Replacement in a Severe Hemophiliac with High-Titer Factor VIII Inhibitor

2002 ◽  
Vol 75 (1) ◽  
pp. 95-99 ◽  
Author(s):  
Marcus E. Carr ◽  
Thomas P. Loughran ◽  
John A. Cardea ◽  
Wade K. Smith ◽  
Jan G. Kuhn ◽  
...  
Keyword(s):  
Total Knee Replacement ◽  
Factor Viii ◽  
Knee Replacement ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
High Titer ◽  
Factor Viii Inhibitor ◽  
Total Knee ◽  
Viii Inhibitor

scholarly journals Total knee replacement with and without emicizumab: a unique comparison of perioperative management

2020 ◽  
Vol 4 (5) ◽  
pp. 855-857
Author(s):  
Matthew S. Evans ◽  
Charles Davis ◽  
M. Elaine Eyster
Keyword(s):  
Total Knee Replacement ◽  
Knee Replacement ◽  
Perioperative Management ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Cost Savings ◽  
Knee Surgery ◽  
Severe Hemophilia ◽  
Key Points ◽  
Total Knee

Key Points Prophylaxis with emicizumab was used in a patient with severe hemophilia with an inhibitor who underwent knee surgery. Use of emicizumab during surgery led to less recombinant factor VIIa and less bleeding, in addition to cost savings, for this patient.

Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa

1999 ◽  
Vol 158 (11) ◽  
pp. 951-952
Author(s):  
E. Lenz ◽  
M. Repas-Humpe ◽  
J. Oldenburg ◽  
W. Kreuz ◽  
W. Schröter ◽  
...  
Keyword(s):  
Factor Viii ◽  
Successful Treatment ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Factor Viii Inhibitor ◽  
Viii Inhibitor
Sign in / Sign up

Export Citation Format

Share Document